PT - JOURNAL ARTICLE AU - Danyuan Xu AU - Kefang Lai AU - Jiaxing Xie AU - Wei Luo AU - Nanshan Zhong TI - Different treatment courses with inhaled corticosteroids for eosinophilic bronchitis DP - 2011 Sep 01 TA - European Respiratory Journal PG - p483 VI - 38 IP - Suppl 55 4099 - http://erj.ersjournals.com/content/38/Suppl_55/p483.short 4100 - http://erj.ersjournals.com/content/38/Suppl_55/p483.full SO - Eur Respir J2011 Sep 01; 38 AB - Background: Eosinophilic bronchitis (EB) is a common cause of chronic cough. Inhaled corticosteroids can improve sputum eosinophilia and cough severity. However, the treatment course with inhaled corticosteroids for EB is unkown.Objective: To observe the efficacy and recurrence in EB patients with different treatment courses of inhaled corticosteroids.Methods: 60 patients diagnosised as EB were randomly divided into three groups with inhaled budesonide 200 μg twice daily via a turbohaler for 4 weeks, 8 weeks and 16 weeks respectively. Cough severity was assessed by visual analogue scale (VAS) and daytime cough symptom score at baseline and during the treatment period. Airway inflamation was assessed by sputum eosinophil count (Eos%). All the patients were followed up for 6 months after treatment.Results: The daytime cough score after treatment decreased in all three group (p<0.05), which was lower in 16 weeks group and 8 weeks group than 4 weeks group (p<0.05). The rate that VAS decreased over 80% after treatment were 55% in 4 weeks group, lower than 8 weeks, 16 weeks group (85%, 95%, p<0.05). The sputum eosinophil count decreased in all three group after treatment. The rate that sputum eosinophil count returned to normal level (Eos%<2.5%) in 8 weeks group (75%), 16 weeks group (95%) were significantly higher than 4 weeks group (50%, p<0.05). The rate of recurrence was 31.3%, 23.5%, 27.8% in 4, 8, 16 weeks group respectively. There are no significant difference among three groups.Conclusion: Our results suggest that eosinophilic brochitis should be treated with low-dose inhaled budesonide for over 8 weeks. Recurrence appear not to be related to treatment course.